What HealthEquity (HQY)'s Strong Q1, Higher Guidance and Buybacks Mean For Shareholders

Simply Wall St.06-08

In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641179001?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063","is_english":true,"pubTime":"2026-06-08 05:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641179001","market":"hk","top_or_hot":-1,"title":"What HealthEquity (HQY)'s Strong Q1, Higher Guidance and Buybacks Mean For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/what-healthequity-hqys-strong-q1-higher-guidance-and-buyback\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What HealthEquity (HQY)'s Strong Q1, Higher Guidance and Buybacks Mean For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat HealthEquity (HQY)'s Strong Q1, Higher Guidance and Buybacks Mean For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-08 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/what-healthequity-hqys-strong-q1-higher-guidance-and-buyback><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/what-healthequity-hqys-strong-q1-higher-guidance-and-buyback\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/what-healthequity-hqys-strong-q1-higher-guidance-and-buyback","article_id":"2641179001","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/what-healthequity-hqys-strong-q1-higher-guidance-and-buyback","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641179001","pubTimestamp":1780867147,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its share repurchase program. \nThe combination of stronger earnings, higher profit expectations for the fiscal year ending January 31, 2027, and completion of a US$244.45 million buyback adds fresh context to analysts’ prior growth and margin assumptions for the business.\nWith HealthEquity lifting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","HQY":"HealthEquity","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4154":"管理型保健护理","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"HealthEquity(HQY)强劲的第一季度、更高的指引和回购对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HQY":1.5},"content_text":"In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its share repurchase program.  The combination of stronger earnings, higher profit expectations for the fiscal year ending January 31, 2027, and completion of a US$244.45 million buyback adds fresh context to analysts’ prior growth and margin assumptions for the business. With HealthEquity lifting full-year earnings guidance, we’ll now examine how this updated outlook affects the existing investment narrative. AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementHealthEquity Investment Narrative RecapTo own HealthEquity, you need to believe in the long term growth of health savings accounts and the company’s ability to translate more accounts and higher balances into durable fee and interest revenue. The latest quarter’s stronger earnings and higher full year guidance support that belief without materially changing the near term catalyst, which is continued account and asset growth, or the key risk around sensitivity to interest income on custodial cash. The most relevant update is HealthEquity’s raised outlook for the fiscal year ending January 31, 2027, now calling for US$1.410 billion to US$1.420 billion in revenue and net income of US$242 million to US$248 million. This sharper earnings view sits alongside completed buybacks and ongoing technology investment, and it frames how much cushion the company might have if interest rates, and therefore custodial yields, move against it. Yet behind the higher guidance, one risk investors should be aware of is how quickly earnings could react if interest income on HSA cash were to... Read the full narrative on HealthEquity (it's free!)HealthEquity's narrative projects $1.7 billion revenue and $357.1 million earnings by 2029. This requires 7.6% yearly revenue growth and a roughly $126 million earnings increase from $230.7 million today.Uncover how HealthEquity's forecasts yield a $114.62 fair value, a 29% upside to its current price.Exploring Other PerspectivesHQY 1-Year Stock Price Chart Three members of the Simply Wall St Community value HealthEquity between US$97.01 and US$166.05, underlining how far apart individual views can be. Against this, the company’s raised earnings guidance and reliance on custodial interest income give you concrete factors to weigh as you compare these alternative perspectives.Explore 3 other fair value estimates on HealthEquity - why the stock might be worth just $97.01!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.Ready To Venture Into Other Investment Styles?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.Outshine the giants: these 13 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HealthEquity might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641179001","isCrawlerRequest":true}